Fig. 5.

Inhibitors targeting HH signaling pathway. In this figure, we mainly show the inhibitors targeting HH signaling pathway, classified according to the properties of the compounds, and the inhibitors in ongoing or completed clinical trials are shown in red. Approved drugs are individually identified, including their indications. BCC basal cell carcinomas, AML acute myeloid leukemia, APL acute promyelocytic leukemia